Atezolizumab is a PD-L1 blocking monoclonal antibody indicated for lung, hepatocellular, bladder and colon cancers, melanoma and alveolar soft part sarcoma, as a single agent or in combination with other anticancer drugs. Atezolizumab received initial U.S. approval in 2016.
- Mechanism
- Curator reviewed · 5 references
PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production. Atezolizumab is a monoclonal antibody that binds PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors. This releases the PD-L1/PD-1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in decreased tumor growth.
- Primary indication
- Atezolizumab has approved indications for the following conditions, with the route of administration being intravenous or subcutaneous in combination with Hyaluronidase (human recombinant), in adult patients: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following...Curator reviewed · 32 structured indications
- Formula / weight
- 145000.0 Da
- First approval
- Canada, 2017 · United States, 2016 · European Union, 2020
- Also known as
- Atezo · Tecentriq
- Code names
- MDPL3280A · MPDL-3280A · MPDL 328OA · RG-7446 · RO-5541267
- Brand names
Resolves to
What you can answer from here — as of October 15, 2026
Which drugs share a target with Atezolizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account